补肝汤治疗肝肾阴虚型慢性乙型肝炎
效果分析及对患者中医证候积分的影响

何瑾瑜; 陈  菲

文章摘要

补肝汤治疗肝肾阴虚型慢性乙型肝炎效果分析及对患者中医证候积分的影响

Analysis of curative effect of Bugan Decoction on CHB of hepatic and renal Yin deficiency type and its influence on TCM syndrome score of patients 1212 HIV (+)antibody screening cases in Wuhan from 2017 to 2023

DOI：10.3969/j.issn.1007-8134.2022.03.010

中文关键词: 补肝汤肝肾阴虚型慢性乙型病毒性肝炎疗效中医证候积分

英文关键词: Bugan Decoction hepatic and renal Yin deficiency type chronic viral hepatitis B curative effect TCM syndrome score

基金项目:陕西省感染性疾病临床医学研究中心（中西医结合）建设项目（2020LCZX-02）；陕西省科技厅重点研发计划项目（2017SF-339）；2018年国家中医药管理局区域中医（肝病）诊疗中心培育单位建设项目；陕西省中医药管理局-长安医学张氏肝病流派传承工作室建设项目（2018）

作者	单位
何瑾瑜	西安，陕西省中医医院肝病科
陈菲	西安，陕西省中医医院老年病科

摘要点击次数: 309

全文下载次数: 0

中文摘要:

[摘要]　目的　观察补肝汤治疗肝肾阴虚型慢性乙型肝炎（chronic hepatitis B, CHB）效果及对患者中医证候积分的影响。方法?选取2018年7月—2020年7月我院收治的肝肾阴虚型CHB患者84例作为研究对象，按随机数字表法分为观察组和对照组，各42例。对照组予常规西药治疗，观察组在常规西药基础上予补肝汤治疗，均持续治疗24周。评价2组疗效，比较中医证候积分、肝功能指标、HBeAg转阴率、HBV DNA转阴率。结果?观察组治疗总有效率为92.86%，高于对照组的69.05%（χ2=7.721，P=0.005）。治疗后，2组各项症状得分均低于治疗前（P均＜0.05），且观察组各项症状得分均低于对照组（P均＜0.05）。治疗后，2组ALT、AST、TBIL水平均低于治疗前（P均＜0.05），ALB水平均高于治疗前（P均＜0.05），且观察组血清ALT [（39.66±9.95） U/L]、AST [（37.89±6.73） U/L]、TBIL [（42.17±8.21） μmol/L]水平均低于对照组[（59.73±13.52）U/L、（46.97±9.64） U/L、（67.52±13.15）μmol/L]（P均＜0.05），血清ALB [（35.88±3.28） g/L]水平高于对照组[（29.73±3.47）g/L] （P＜0.05）。观察组HBeAg转阴率为40.48%（17/42），高于对照组的19.05%（8/42）（P＜0.05）。2组HBV DNA转阴率均为100%。结论?在常规西药治疗基础上，采用补肝汤治疗肝肾阴虚型CHB患者，有助于减轻症状，改善肝功能，促进HBeAg、HBV DNA转阴，提高疗效。

英文摘要:

[Abstrac] ?Objective?To observe the curative effect of Bugan Decoction in treating chronic viral hepatitis B (CHB) of hepatic and renal Yin deficiency type and its influence on TCM syndrome scores of patients. Methods?From July 2018 to July 2020, 84 CHB patients of hepatic and renal Yin deficiency type admitted to this hospital were randomly divided into study group and control group, with 42 cases in each group. The control group was treated with conventional western medicine; The study group was treated with Bugan Decoction on the basis of conventional western medicine, and the treatment was continued for 24 weeks. The efficacy of the 2 groups was evaluated, the TCM syndrome scores, liver function indicators, hepatitis B virus e antigen (HBeAg) conversion rate, and HBV-DNA conversion rate were compared. Results?The total effective rate of the study group was 92.86% higher than that of the control group 69.05% (χ2=7.721, P=0.005). After treatment, the scores of all symptoms in the 2 groups were lower than those before treatment ( P＜0.05), and the scores of all symptoms in the study group were lower than those in the control group ( P＜0.05). After treatment, the serum ALT, AST, TBIL levels of 2 groups were lower than before treatment (P＜0.05), and the serum ALB level was higher than before treatment (P＜0.05), and the serum ALT [(39.66±9.95) U/L], AST [(37.89±6.73) U/L], TBIL [(42.17±8.21) μmol/L] levels in the study group were lower than those in the control group [(59.73±13.52) U/L, (46.97±9.64) U/L, (67.52±13.15) μmol/L] ( P＜0.05), and the serum ALB [(35.88±3.28) g/L] level was higher than that in the control group [(29.73±3.47) g/L] (P＜0.05). The negative conversion rate of HBeAg in the study group was 40.48% (17/42) higher than that in the control group 19.05% (8/42) (P＜0.05), and the negative conversion rate of HBV-DNA was all 100%. Conclusions?On the basis of conventional western medicine treatment, Bugan Decoction is used to treat CHB with hepatic and renal Yin deficiency type, which is helpful to reduce symptoms, improve liver function, promote the negative conversion of HBeAg and HBV-DNA, and improve the curative effect.

HTML 查看全文下载PDF阅读器

关闭